Research programme: inhaled pirfenidone - Genoa Pharmaceuticals

Drug Profile

Research programme: inhaled pirfenidone - Genoa Pharmaceuticals

Alternative Names: Aerodone™; Aerosol pirfenidone; GP-101

Latest Information Update: 06 Aug 2014

Price : $50

At a glance

  • Originator Genoa Pharmaceuticals
  • Developer Genoa Pharmaceuticals; McMaster University
  • Class
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis

Most Recent Events

  • 15 May 2017 Genoa Pharmaceuticals plans a clinical trial for Idiopathic pulmonary fibrosis towards the end of 2017
  • 05 Aug 2014 Inhaled pirfenidone receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
  • 17 Jun 2013 Preclinical pharmacodynamics data in Pulmonary fibrosis released by Genoa Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top